2-hydroxy-5-methyl-benzoic acid p-anisidide | 78417-75-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-5-methyl-benzoic acid p-anisidide
• 英文别名: 2-Hydroxy-5-methyl-benzoesaeure-p-anisidid；2-hydroxy-N-(4-methoxyphenyl)-5-methyl-benzamide；2-hydroxy-N-(4-methoxyphenyl)-5-methylbenzamide
• CAS: 78417-75-1
• 化学式: C₁₅H₁₅NO₃
• 分子量: 257.289
• InChiKey: ZYHRQCXOFASDGR-UHFFFAOYSA-N

物化性质

• 熔点：
  182-184 °C
• 沸点：
  361.3±42.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-hydroxy-5-methyl-benzoic acid p-anisidide 、 氯甲酸乙酯 在 盐酸 作用下， 以 吡啶 为溶剂， 反应 25.0h， 以68%的产率得到3-(4-Methoxy-phenyl)-6-methyl-benzo[e][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  Waisser, Karel; Bures; Holy, Pharmazie, 2003, vol. 58, # 2, p. 83 - 94

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲基水杨酸 在 三氯化磷 作用下， 以 氯苯 为溶剂， 反应 3.25h， 生成 2-hydroxy-5-methyl-benzoic acid p-anisidide
  参考文献：
  名称：

  Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus

  摘要：

  A series of 55 salicylamides, including 3,5-dibromo-, 5-n-alkyl-, and 5-n-acylsalicyloyl derivatives of various anilines, heterocyclic amines, benzylamines, and alkylamines, was synthesized and evaluated for in vitro antibacterial activity against Actinomyces viscosus, an adherent oral microorganism implicated in periodontal disease. The in vitro minimum inhibitory concentrations of 15 4'-bromosalicylanilides were found to correlate (r = 0.92) with estimated log D values. Several nonhalogenated salicylanilides, such as 5-n-hexyl- (40) and 5-n-decanoyl-4'-nitrosalicylanilide (47), were found to exhibit higher levels of in vitro antibacterial activity against a number of Actinomycetes than did tribromsalan (1) or fluorophene (2).

  DOI：

  10.1021/jm00142a023

文献信息

• Relationship between the Structure and Antimycobacterial Activity of Substituted Salicylanilides
  作者：Karel Waisser、Otakar Bureš、Pavel Holý、Jiří Kuneš、Radek Oswald、Lucie Jirásková、Milan Pour、Věra Klimešová、Lenka Kubicová、Jarmila Kaustová

  DOI：10.1002/ardp.200390004

  日期：2003.3

  A series of 143 salicylanilides substituted in positions 4 and 5 and in positions 3′ and 4′ was synthesized. The compounds were evaluated for in vitro antimycobacterial activity against Mycobacterium tuberculosis, Mycobacterium kansasii, and Mycobacterium avium. To describe the structure‐antimycobacterial activity relationships (QSARs), an approach based on the combination of the Free‐Wilson and Hansch

  合成了一系列在 4 和 5 位以及在 3' 和 4' 位被取代的 143 个水杨酰苯胺。评估了化合物对结核分枝杆菌、堪萨斯分枝杆菌和鸟分枝杆菌的体外抗分枝杆菌活性。为了描述结构-抗分枝杆菌活性关系（QSAR），采用了一种基于 Free-Wilson 和 Hansch 方法组合的方法（在苯环上的取代基的情况下使用取代基常数；指示参数用于酰基部分上的取代基）。还探讨了所有替代品的抗分枝杆菌活性与理化参数之间的关系。亲脂性参数的二次表示没有导致显着的相关性。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Muto Susumu

  公开号：US20070276011A1

  公开（公告）日：2007-11-29

  A medicament having inhibitory activity against plasminogen activator inhibitor-1, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein R 1 and R 2 represents an aromatic group which may be substituted, W represents a group selected from the following connecting group W-1: (wherein a bond at the left end binds to the carbon atom and a bond at the right end binds to the nitrogen atom, X represents sulfur atom or NH, Y represents oxygen atom or sulfur atom, R 3 represents a hydrocarbon group, hydroxy group, or carboxy group), Z represents a single bond or a connecting group wherein a number of atoms in a main chain is 1 to 3.

  一种具有抑制纤溶酶原激活物抑制剂-1活性的药物，其包含以下通式（I）或其盐作为活性成分的化合物：其中R1和R2代表可以被取代的芳香基团，W代表以下连接基团之一：（其中左端的键结合到碳原子，右端的键结合到氮原子，X代表硫原子或NH，Y代表氧原子或硫原子，R3代表烃基团，羟基或羧基），Z代表单键或连接基团，其中主链中的原子数为1到3。
• Trifluoroacetic Acid-Mediated Denitrogenative <i>ortho</i>-Hydroxylation of 1,2,3-Benzotriazin-4(3<i>H</i>)-ones: A Metal-Free Approach
  作者：Kanagaraj Madasamy、Madasamy Hari Balakrishnan、Ramaraju Korivi、Subramaniyan Mannathan

  DOI：10.1021/acs.joc.2c00354

  日期：2022.7.1

  An efficient trifluoroacetic acid-mediated denitrogenative hydroxylation of 1,2,3-benzotriazin-4(3H)-ones is described. This metal-free approach is compatible with a wide range of 1,2,3-benzotriazin-4(3H)-ones, affording ortho-hydroxylated benzamides in good to high yields with a short reaction time. The reaction is believed to proceed via a benzene diazonium intermediate. The synthetic utility of

  描述了一种有效的三氟乙酸介导的 1,2,3-benzotriazin-4(3 H )-ones 的脱氮羟基化。这种不含金属的方法与多种 1,2,3-benzotriazin-4(3 H )-one相容，可在较短的反应时间内以良好至高产率提供邻羟基化苯甲酰胺。据信该反应通过苯重氮中间体进行。该反应的合成效用通过以良好收率制备抗微生物药物利肝素 C 和苯并恶嗪-2,4(3 H )-二酮类化合物得到成功证明。
• [EN] SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS<br/>[FR] INHIBITEURS À PETITES MOLÉCULES D'INFECTIONS PAR SARS-COV-2
  申请人：THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES

  公开号：WO2022109148A1

  公开（公告）日：2022-05-27

  The present disclosure relates generally to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly referred to as coronavirus disease 2019 (COVID-19). The present disclosure relates more particularly to small molecule inhibitors of SARS-CoV-2 of Formula (II) and prodrug derivatives thereof of Formula (I), and methods of treating COVID-19 therewith.

  本公开涉及化合物、包含它们的药物组合物以及使用这些化合物和组合物治疗由严重急性呼吸综合症冠状病毒2（SARS-CoV-2）引起的疾病，通常称为2019冠状病毒病（COVID-19）的方法。本公开特别涉及SARS-CoV-2的小分子抑制剂II式和其前药衍生物I式，以及使用它们治疗COVID-19的方法。
• Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus
  作者：Robert A. Coburn、Armando J. Batista、Richard T. Evans、Robert J. Genco

  DOI：10.1021/jm00142a023

  日期：1981.10

  A series of 55 salicylamides, including 3,5-dibromo-, 5-n-alkyl-, and 5-n-acylsalicyloyl derivatives of various anilines, heterocyclic amines, benzylamines, and alkylamines, was synthesized and evaluated for in vitro antibacterial activity against Actinomyces viscosus, an adherent oral microorganism implicated in periodontal disease. The in vitro minimum inhibitory concentrations of 15 4'-bromosalicylanilides were found to correlate (r = 0.92) with estimated log D values. Several nonhalogenated salicylanilides, such as 5-n-hexyl- (40) and 5-n-decanoyl-4'-nitrosalicylanilide (47), were found to exhibit higher levels of in vitro antibacterial activity against a number of Actinomycetes than did tribromsalan (1) or fluorophene (2).